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Key Points
•Novel CD45–F4/80lo
marrow cells are de-
velopmentally derived
from hematopoietic
progenitors and reside
among the endosteal
osteoblasts.
• In situ depletion of
CD45 cells before
marrow radioablation
results in flattened os-
teoblasts and absent
HSC engraftment.
Hematopoietic stem cells (HSCs) reside in specializedmicroenvironmentswithin themarrow
designated as stem cell niches, which function to support HSCs at homeostasis and promote
HSC engraftment after radioablation. We previously identified marrow space remodeling
after hematopoietic ablation, including osteoblast thickening, osteoblast proliferation, and
megakaryocyte migration to the endosteum, which is critical for effective engraftment of
donorHSCs. To further evaluate the impact of hematopoietic cells onmarrowremodeling,we
used a transgenic mouse model (CD45Cre/iDTR) to selectively deplete hematopoietic cells in
situ. Depletion of hematopoietic cells immediately before radioablation and hematopoietic
stem cell transplantation abrogated donor HSC engraftment and was associated with
strikingly flattened endosteal osteoblasts with preserved osteoblast proliferation and
megakaryocyte migration. Depletion of monocytes, macrophages, or megakaryocytes (the
predominant hematopoietic cell populations that survive short-term after irradiation) did
not lead to an alteration of osteoblast morphology, suggesting that a hematopoietic-derived
cell outside these lineages regulates osteoblast morphologic adaptation after irradiation.
Using 2 lineage-tracing strategies, we identified a novel CD45–F4/80lo HSC-derived cell that
resides among osteoblasts along the endosteal marrow surface and, at least transiently,
survives radioablation. This newly identified marrow cell may be an important regulator
of HSC engraftment, possibly by influencing the shape and function of endosteal osteoblasts.
Introduction
Hematopoietic stem cells (HSCs) reside in specialized microenvironments within the marrow that are
designated stem cell niches. At homeostasis, the niche functions to maintain HSC quiescence,
proliferation, and fate allocation, and after hematopoietic stem cell transplant (HCT) conditioning, it
facilitates donor HSC engraftment, survival, and proliferation.1 Hastening engraftment and hematopoi-
etic reconstitution would represent a major advance in clinical HCT; however, such research is
contingent upon a more complete understanding of the biology of the postablation niche, which is clearly
distinct from niche biology during homeostasis.
The exact location and constituents of the hematopoietic niche have been widely explored and debated
over the past few decades. Although our understanding of the hematopoietic niche continues to evolve,
our current view is that at homeostasis, the marrow stem cell niche comprises many cell types and
signals, including the arteriolar niche and the sinusoidal-megakaryocyte niche.1-3 Osteolineage cells are
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a constituent of both niches4-6; however, the precise role of mature
osteoblasts in HSC maintenance remains controversial. Adipocytes
have also been investigated for their role in hematopoiesis, although
their role is unclear at this time.7,8
The adaptive potential of these cellular microenvironments to
respond to both pathological and physiological changes highlights
the complex and vital interactions of the cellular constituents of the
niche as well the important differences between homeostasis and
postablated marrow niches. Successful hematopoietic reconsti-
tution of donor HSC after HCT is dependent on a number of
intricate cellular interactions, including recovery of the sinusoidal
endothelium,1,9-11 migration of megakaryocytes to the endosteal
space, and osteoblast proliferation.12 The role played by
megakaryocytes in this niche is evidence of this adaptation
because megakaryocytes function to promote quiescence via
CXCL413 and TGF-b14 at homeostasis and support HSC
proliferation by secretion of fibroblast growth factor 1 (FGF1)2
after HCT.2,11,13 In addition, osteolineage cells may play a greater
role in this adaptation than previously believed because primitive
hematopoietic cells seem to initially localize to the osteoblast
surface after HCT,15,16 underscoring the importance of osteo-
blasts in the postablated marrow niche.
Here, we report that in situ targeted depletion of hematopoietic cells
immediately before marrow radioablation abrogated donor HSC
engraftment after HCT and was associated with strikingly flattened
endosteal osteoblasts that failed to undergo normal conformational
changes induced by radioablation. By using 2 lineage-tracing
strategies, we identified a novel CD45–F4/80lo HSC-derived cell
that resides among osteoblasts along the endosteal marrow surface
and, at least transiently, survives radioablation. This newly identified
marrow cell may be an important regulator of HSC engraftment,
possibly by directing adaptations of the endosteal osteoblasts to
myeloablative HCT conditioning.
Materials and methods
Mice and irradiation
Experiments were conducted in accordance with protocols
approved by Institutional Animal Care and Use Committee, and
colonies were housed and maintained in the vivarium at The
Research Institute at Nationwide Children’s Hospital. All mice were
purchased from The Jackson Laboratory with the exception of the
CD45Cre strain that was originally obtained from Eva Mezey, MD
(National Institutes of Health).17 The Cre/loxP system18 was used to
generate double transgenic F1 mice expressing the inducible
diphtheria toxin receptor (iDTR) in specific Cre-expressing cell
targets as described by Buch et al19 or in Z/RED20 or Ai921 mice in
lineage-tracing models. Triple transgenic F2 mice were developed
by crossing cell-specific Cre/iDTR, cell-specific Cre/Z/RED, or Ai9
F1 mice with the Col2.3GFP strain22 (for all mouse strains, see
supplemental Table 1). Mice ranged in age from 6 to 18 weeks at
the start of experiments. Total body irradiation (TBI) was performed
by using a radiograph source (X-RAD 320, Precision X-ray Inc.).
Five or more mice were used for all experiments unless otherwise
specified.
In vivo cell depletion
Bone marrow hematopoietic cells were depleted in double-
transgenic mice expressing iDTR on CD45-17 or Vav1-expressing23
cells. Mice received 100 ng of diphtheria toxin (DT) intraperitoneally
24 hours before TBI (1000 cGy) and were analyzed 48 hours after
irradiation. Monocytes, macrophages, or megakaryocytes were
depleted in transgenic mice expressing iDTR on lysozyme2-
expressing (LYZ-Cre)24 or PF4-expressing cells,25,26 respectively.
Mice received daily intraperitoneal injections of DT (100 ng) for
6 days, received TBI on day 4 (1000 cGy), and were analyzed
48 hours after irradiation. Chemical depletion of monocytes and
macrophages27 was accomplished by tail vein injection of
clodronate (500 ng/day) for 5 days and TBI on day 4. All depletion
models were monitored by peripheral blood counts on a Hemavet
(Drew Scientific Inc.), and bone marrow (BM) was analyzed
by flow cytometry and histology at 48 hours after irradiation.
C57BL/6 mice and wild-type (WT) littermates were assessed in
parallel as controls.
Histology studies
Mouse bones were fixed, decalcified, and paraffin embedded as
previously described.12,28 Briefly, femora and tibiae were fixed in
either 10% neutral buffered formalin or 4% paraformaldehyde for
48 hours. Bones were then decalcified with either Regular Cal
Immuno (BBC Biochemical, Mount Vernon, WA) for 5 to 7 days or
15% EDTA for 3 weeks before dehydration and paraffin embed-
ding. Histologic sections were evaluated on an AxioImager
200M (Carl Zeiss, Thornwood, NY) or Zeiss 510 confocal
microscope (Carl Zeiss) using 633/1.4NA oil, 203/0.5NA dry,
and 403/0.75NA dry objectives. Photographs were obtained with
an Axiocam HRc or MRm camera and evaluated by using AxioVision
4.5SP1 software.
High-power fields (HPFs [203]) of metaphyseal BM were
examined, and the thickness of bone-lining cells was measured
from at least 6 sections from each animal (n$ 5.) For assessment of
osteoblast proliferation, the osteoblast score index was evaluated,
as described by Caselli et al,28 which represents the average
number of endosteal lining cell layers per section. The mean of
5 sections was taken as the individual mouse score. CD41-stained
sections of metaphyseal BM were analyzed for total number and
location of megakaryocytes at either the endosteal surface (within 1
cell diameter) or within the marrow space. At least 4 HPFs per
section and more than 2 sections per mouse were averaged (n. 4
mice per group). Histologic assessment of cell-specific depletion
was accomplished by immunohistochemistry (IHC) and/or immu-
nofluorescence (IF) (see supplemental Data).
Secondary transplantation assay
A competitive secondary transplantation assay was performed as
previously described by Olson et al.12 Briefly, primary recipient
CD45Cre or WT littermates underwent DT depletion (100 ng/day)
followed by TBI (1000 cGY in split dosing). Mice were transplanted
48 hours later with 400 000 BM cells from H2K-GFP donor mice via
tail vein injection. Thirty hours after transplant, BM was collected
from primary recipients (n 5 5 per cohort), pooled, and injected
into irradiated WT secondary recipient mice (n 5 15) along with
200 000 nonirradiated WT BM cells. Secondary recipients were
assessed by peripheral blood analysis at 3, 8, and 16 weeks for
percentages of green fluorescent protein (GFP)–expressing cells.
BM analysis for the presence of GFP positivity was performed at
16 weeks to evaluate the effectiveness of primary recipient long-
term HSC (LT-HSC) engraftment defined as .1% GFP.12
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Flow cytometric measurements
Flow cytometry analysis was performed on BD FACSCalibur and
BD LSRII (BD Biosciences, San Jose, CA) cytometers using
commercially available antibodies (BD Biosciences). Lineage (Lin)
staining included anti-mouse TER119, GR1, B220, CD4 (RM4-5),
CD8 (53-6.7), and CD11b (M1/70). Data were analyzed by using
FlowJo version 10.0.6 software (Tree Star, Inc.). For flow cytometric
analysis of bone-lining cells, marrow was vigorously flushed from the
marrow space into fluorescence-activated cell sorting buffer. Bones
were digested with collagenase P, and all washings were added to
the collected marrow.
Statistical analysis
Statistical analyses were performed by using either unpaired two-
tailed Student t test or one-way analysis of variance with multiple
comparisons on Prism Version 6 (GraphPad Software Inc.,
La Jolla, CA). A minimum of 3 replicates were used for statistical
analyses for each experiment. All statistical data are shown with
mean 6 standard error of the mean. P , .05 was considered
statistically significant.
Results
In situ depletion of host hematopoietic cells before
HSC transplant results in decreased donor
HSC engraftment
To examine the effect of hematopoietic cell regulation of marrow
remodeling and engraftment, we bred mice expressing Cre
recombinase under the control of the CD45 promoter (CD45Cre)
with iDTR transgenic mice to generate mice with DTR expression on
hematopoietic cells. Importantly, all cells derived from CD45-
expressing precursors, such as megakaryocytes, express DTR and
can be selectively depleted, even if the mature cell lacks CD45
expression. To first validate the fidelity of the CD45Cre construct, we
bred these mice to express a red fluorescent protein (RFP) reporter.
Flow cytometric analysis of the CD45Cre/Z/RED mice showed RFP
expression in 93% of the CD451 population in peripheral blood and
in 91% of the CD451 population in BM.29 We did not identify RFP
expression in other tissues. We then generated CD45-driven DTR-
expressing mice and used their CD45Cre– littermates as negative
controls. Treatment with a single dose of 100 ng of DT yielded an
85% depletion of the leukocytes (CD45Cre1, 0.566 0.173 109/L;
Cre–, 6.59 6 1.89 3 109/L; P 5 .0053) and 65% depletion of the
platelets (CD45Cre1, 7696 2173 109/L; Cre–, 2836 1373 109/L;
P 5 .0304) (Figure 1A), validating our in situ depletion model.
When mice underwent DT-mediated depletion of CD45-
expressing cells followed by conventional radioablation and
transplantation with normal marrow, all animals died before
hematopoietic reconstitution. Because relatively few primitive
hematopoietic cells are required to repopulate the marrow,30 this
observation suggested that the DT depletion created a defect in
the host marrow microenvironment that diminished receptivity for
transplanted HSCs.
We sought to determine whether the underlying failure of hemato-
poietic reconstitution in the CD45-depleted primary recipients is a
modification of the donor LT-HSC ability to home and adhere within
the marrow space or survive and proliferate within the niche once
established in the marrow space. To distinguish between these
2 mechanisms, we assessed initial engraftment of long-term
hematopoietic repopulating cells by using our semiquantitative
competitive secondary transplantation assay12 (Figure 1B), which
tests for initial engraftment of LT-HSCs in the primary recipients.
Surprisingly, only 1 of 15 of the secondary recipients of CD45-
depleted primary mice had LT-HSC engraftment defined by .1%
GFP expression compared with 10 of 15 control mice (P 5 .0017)
(Figure 1C), confirming a striking deficit of initial HSC homing and
adherence in the DT-depleted primary recipients.
Osteoblast flattening associated with in situ
depletion of hematopoietic cells
At homeostasis, the endosteal surface is lined with a single layer of
cuboidal osteoblasts and well-defined endothelial cells forming the
marrow vasculature. Marrow megakaryocytes reside near the
vasculature with only 8.60% 6 0.17% proximate to the endosteal
surface (supplemental Figure 1A). In contrast, 48 hours after
hematopoietic radioablation, the endosteal lining osteoblasts have
proliferated to 2.646 0.08 layers (P, .0001) and thickened from a
baseline of 4.60 6 0.23 mm to 8.17 6 0.16 mm (P , .0001)
(Figure 2A-B; supplemental Figure 1B-C). The vasculature was not
clearly defined, and 40.70% 6 0.31% of the remaining megakar-
yocytes had migrated to the endosteal region, all consistent with our
previous observations.12,28,31
Histologic assessment of femurs from mice treated with DT and TBI
revealed proliferative, but significantly flattened osteoblasts
(cell thickness, 3.42 6 0.10 mm) in iDTR-expressing mice
compared with similarly treated littermate controls (cell thickness,
8.45 6 0.31 mm; P , .0001; Figure 2A-B), suggesting that
depletion of host hematopoietic lineages is associated with the
regulation of osteoblast morphology as well as donor HSC
engraftment. Interestingly, osteoblast thickness in iDTR mice
treated with DT only (no TBI) was significantly decreased compared
with that in WT controls treated with DT (cell thickness, 2.89 6
0.13 mm in iDTR mice vs 4.60 6 0.23 mm in controls; Figure 2B).
The total number of megakaryocytes in treated mice were
significantly decreased compared with that in control mice (3.33
6 0.54 cells per HPF in the CD45-depleted cohort vs 7.07 6 0.60
cells per HPF in Cre– littermates; P 5 .0001). However, of the
remaining megakaryocytes, 33.3% 6 1.3% migrated to the
endosteal surface, suggesting that the migratory capacity of
megakaryocytes surviving the DT-mediated in situ depletion
remained intact. Finally, assessment of BM morphology after
myeloablative busulfan and cyclophosphamide (without TBI) was
comparable to that seen after myeloablative TBI used in these
experiments (T.S.O. and E.M.H., unpublished observation); thus, our
results are not dependent on radioablation.
To confirm these findings, we repeated these experiments using an
alternative double transgenic mouse that expressed Cre under the
control of the Vav1 promoter (Vav1Cre) crossed with iDTR. Flow
cytometric analysis of BM from Vav1Cre mice crossed with the RFP
reporter mice showed 86.9%6 7.8% of DsRed positivity within the
CD45 population. Forty-eight hours after TBI of DT-treated DTR-
expressing mice and their control littermates, histologic analysis
showed that osteoblast morphology was again significantly
flattened (4.55 6 0.08 mm) compared with that of irradiated
littermate controls (7.16 6 0.43 mm; P , .0001), similar to our
findings using the CD45Cre model (Figure 2C-D). Consistent
results using 2 different transgenic promoters driving Cre
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expression suggested that a model-independent regulatory mech-
anism involving cells derived from hematopoietic lineages is
responsible for driving osteoblast morphologic changes that
correlate with successful HSC engraftment after HCT.
Because earlier studies have shown the importance of osteoblast
size and shape for both hematopoiesis32 and retention or egress of
HSCs from the BM,33,34 we sought to determine how closely
radioablation-induced changes in osteoblast thickness can serve as
an index for the niche capacity to engraft donor HSCs. Our data
implicate host CD45-expressing cells that persist after radioablation
as regulatory components of this morphologic adaptation. Mega-
karyocytes (which are known to remain functional in murine models
7 to 10 days after irradiation31) and monocytes and macro-
phages that survive short-term after irradiation33 were our most
likely candidates. Analyses of WT mice 48 hours after irradiation
confirmed the survival of these 2 dominate hematopoietic
populations in BM.31
In situ depletion of monocytes and macrophages
does not alter post-TBI osteoblast morphology
To evaluate the role of monocytes and macrophages on osteoblast
enlargement, we depleted these cells in situ using 2 models. First,
we generated mice expressing DTR directed by the lysozyme
promoter LYZ/iDTR, which predominately but not exclusively labels
monocytes and macrophages. Second, we used a pharmacologic
depletion with clodronate, given recent studies that showed varying
results between the 2 depletion methods.33 Flow cytometric analysis
(Figure 3A) of the CD11b BM population decreased from an average
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Figure 1. LT-HSC engraftment after BM transplantation is significantly impaired after hematopoietic cell depletion. (A) Peripheral blood analysis 48 hours after a
single injection of 100 ng DT showed a significant depletion of leukocytes and platelets. (B) Pictogram describing a secondary transplant assay that used a GFP1 BM
donation to DT-depleted and irradiated primary recipients. Primary BM was then transplanted along with WT competitor BM into irradiated WT secondary recipients. Bone
marrow analysis for the presence of GFP positivity was performed at 16 weeks to evaluate the effectiveness of primary recipient LT-HSC engraftment defined as .1% GFP.
(C) Flow cytometric analysis of mouse BM 16 weeks after secondary transplant assay evaluating the LT-HSC engraftment. WBC, white blood cell count.
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of 13.86% 6 2.41% to 3.15% 6 0.58% in the LYZ/iDTR cohort,
which represents an 80% depletion (P 5 .003) and 24.9% 6 2.45%
to 10.6% 6 2.26% in the clodronate cohort (P 5 .005) in irradiated
mice. Analysis of the F4/80 BM populations in the LYZ/iDTR cohort
showed 75% depletion, with a decrease from 1.70% 6 0.30% to
0.38% 6 0.70% (P 5 .008), and the clodronate cohort showed a
decrease from 2.37% 6 .44% to 0.96% 6 .07% (P 5 .015) in
irradiated mice.
Osteoblast enlargement was preserved with both depletion
methods compared with that in untreated littermate controls (cell
thickness, 7.35 6 0.76 mm vs 3.16 6 0.57 mm [P , .0001] in the
LYZ cohort and 6.446 0.84 mm vs 3.166 0.57 mm [P, .0001] in
the clodronate cohort) and DT- treated and irradiated control group
(cell thickness, 7.35 6 0.76 mm vs 7.16 6 0.43 mm [P 5 ns] in the
LYZ cohort and 6.446 0.84 mm vs 6.846 0.42 mm [P5 ns] in the
clodronate cohort) (Figure 3B-C). Although we did not obtain
complete depletion with either model, we used 2 very different
depletion strategies to most thoroughly assess for a monocyte or
macrophage contribution. Our data suggest that classic monocytes
and macrophages are not responsible for morphologic changes of
endosteal osteoblasts.
In situ depletion of megakaryocytes does not alter
post-TBI osteoblast morphology
The megakaryocyte population was then evaluated as the osteoblast
regulatory population because megakaryocytes have been shown to
remain functional for 7 to 10 days after irradiation and extensively
interact with the endosteal bone.31,35 Megakaryocytes were depleted
in PF4Cre/iDTR mice with DT injections, and mean platelet counts
decreased by 85% compared with those in DT-treated littermate
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Figure 2. BM remodeling and osteoblast morphology after hematopoietic cell depletion and TBI. (A) Hematoxylin and eosin (H&E)–stained and GFP-stained
sections (403) of metaphyseal BM 48 hours after both DT depletion and TBI in CD45Cre– (control) and CD45Cre1-depleted mice demonstrating depletion of hematopoietic
cells and alterations in osteoblast (OB) thickness. (B) Quantitative analysis of osteoblast thickness (n $ 5) after DT injection only, TBI only, or DT injection and TBI in
mice expressing iDTR with and without the presence of CD45Cre cells. Results show a significant decrease in osteoblast thickness (3.42 6 0.11 mm vs WT, 8.45 6 0.31 mm;
P , .0001) between mice treated with DT and TBI in the CD45Cre1 cohort. There was also a significant decrease between CD45Cre– and CD45Cre1 mice treated with
DT injection only (4.60 6 0.23 mm in CD45Cre– vs 2.89 6 0.13 mm in CD45Cre1; P , .0001). (C) H&E-stained and GFP-stained sections (403) of metaphyseal BM
48 hours after DT injection and TBI in Vav1Cre– (control) and Vav1Cre1-depleted mice (n $ 5). (D) Analysis of osteoblast thickness in Vav1 depletion model confirming
osteoblast flattening (4.55 6 0.08 mm vs WT, 7.16 6 0.43 mm; P , .0001).
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controls (n$ 6) (PF4/iDTR, 116.96 42.63 109/L; treated controls,
808.6 6 153 3 109/L; P 5 .0007) (Figure 4B). Flow cytometry
confirmed an 83% depletion of CD411 cells, with the population
decreasing from 32.2% 6 5.7% to 5.69% 6 1.70% (P 5 .002)
(Figure 4A). IF and IHC evaluation visually confirmed a significant
reduction of the CD411 cell population in PF4/iDTR mice compared
withWT littermates (2.86 0.3 cells vs 7.076 0.61 cells; P5 .0005)
(Figure 4C).
Analysis of postirradiation osteoblast thickness after megakar-
yocyte depletion revealed a statistically significant increase in
osteoblast thickness compared with that in untreated controls
(cell thickness, 7.51 6 0.62 mm vs 3.16 6 0.57 mm; P , .0001)
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Figure 4. Effect of megakaryocyte depletion on osteoblast thickening. (A) Flow cytometric analysis of peripheral blood at days 0, 3, and 6 of DT injections showing
depletion of peripheral platelets (top) and flow cytometric analysis of BM from PF4/iDTR mouse after 5-day treatment with DT and 48 hours after irradiation showing depletion
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and in the DT-treated and irradiated control group (cell thickness,
7.51 6 0.62 mm vs 7.16 6 0.43 mm; P 5 ns) (Figure 4C-D).
Although the number of megakaryocytes significantly decreased
(2.96 6 0.82 cells per HPF vs 7.10 6 1.43 cells in controls
per HPF), megakaryocyte migration (;40% of the remaining
cells) was consistent with that in irradiated WT mice, which
may in part underlie the unimpaired osteoblast proliferation.
These data suggests that although megakaryocytes are impor-
tant for osteoblast proliferation, they do not drive the osteo-
blast morphologic change seen in our CD45-lineage depletion
model.
Identification of a novel CD45–F4/80lo bone-lining cell
as a candidate regulatory element
To identify other candidates for the osteoblast morphology
regulatory cells, we used 2 lineage-tracing strategies (CD45- and
Vav1-directed RFP) to reveal hematopoietic cells that survive, at
least short-term, after radioablation. Surprisingly, we identified a
novel cell residing in the bone marrow among endosteal osteoblasts
that was developmentally derived from a hematopoietic progenitor
(as identified by the RFP lineage reporter) but lacked CD45
expression (Figure 5A). When CD45/Z/RED mice were crossed
with Col2.3GFP transgenic mice (which express GFP in mature
osteoblasts22), RFP-expressing bone-lining cells lacked GFP co-
expression by IHC staining (Figure 5B) and flow cytometry,29
indicating they are not mature osteoblasts.
By using confocal microscopy with IF staining, we determined that
these CD45–RFP1 cells lacked expression of lineage markers
(including Gr1, CD11b, CD3, B220, Ter119; Figure 5C) and
cathepsin K,29 indicating they are not conventional hematopoietic
cells, specifically not osteoclasts; nonetheless, they were derived
from CD45-expressing progenitors (Figure 5B). With confocal
microscopy, we visualized individual CD45–Lin–RFP1 cells
along the endosteum, confirming the identification of a novel
hematopoietic lineage–derived (RFP expression) bone-lining cell
(Figure 5C).
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Figure 5. CD45Cre-labeled murine BM. (A) IF-stained metaphyseal bone sections (203) of RFP-labeled CD45Cre mouse showing BM at homeostasis. White arrows
indicate a red CD45-derived cell that resides near the endosteal region. Green CD45 stain reveals that the cell no longer expresses CD45. (B) IF metaphyseal section (403)
of BM from DsRed-labeled CD45Cre mouse crossed with a Col2.3GFP mouse, which GFP labels mature osteoblast. White arrowhead indicates the red CD45-derived cell;
green arrowhead indicates the GFP-labeled mature osteoblast. (C) Confocal Z-stack image (633) showing RFP Vav1-derived cell that does not stain for lineage markers
(B220, CD3, Ter119, Gr1, CD11b). (D) Flow cytometric analysis of transgenic CD45/Ai9 mouse BM and bone-lining cells gated on DsRed1/CD45– population. (E) Dot plot
and histogram depiction of transgenic CD45/Ai9 mouse BM and bone-lining cells gated on DsRed1/CD45– population showing shift of F4/80 expression. F4/80 expression
on dot plot showed an average of 17.27% 6 3.6% positivity vs 1.1% 6 0.015% in unstained controls. (F) Flow cytometric analysis of WT mouse BM and bone-lining cells
gated on CD45– population. F4/80 expression on dot plot analysis showed an average of 13.5% 6 0.8% positivity vs 1.1% 6 0.015% in unstained controls.
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Flow cytometric characterization of freshly isolated CD45–RFP1 cells
confirmed that these cells lacked most hematopoietic antigens but
revealed F4/80 expression (Figure 5D). Compared with conventional
CD451F4/801 monocytes, F4/80 expression was low but un-
equivocal, most likely indicating low expression on a relatively small
population in the marrowmicroenvironment (Figure 5E). Conceivably,
lineage tracing may have revealed a heterogeneous population of
RFP1 cells with a continuum of detectable F4/80 expression.
Although F4/80 expression is considered to be a marker of the
monocyte/macrophage family in mice, these cells lacked expression
of other monocyte/macrophage surface markers such as CD11b,
CD115, CD14, CD166, and CD169 (Figure 5D) as well as the
leukocyte marker CD45. Collectively, our data suggest that the
phenotype CD45–F4/80lo specifically identifies this novel
hematopoietic-derived bone-lining cell.
Because DT depletion of CD45-derived cells just before hematopoi-
etic radioablation leads to poor donor HSC engraftment and flattened
osteoblasts, a morphology not observed with depletion of classically
defined monocytes and macrophages or megakaryocytes, we
postulated that the CD45–F4/80loRFP1 cell is a candidate regulatory
cell for endosteal osteoblast function. Consistent with this notion, the
frequency of CD45–RFP1 cells is greater in the metaphysis (the site of
initial donor HSC engraftment31,36) compared with the diaphysis, and
these cells expand similarly to endosteal osteoblasts after marrow
radioablation. Most intriguing, CD45–F4/80loRFP1 cells seem to
express nestin by reverse transcription polymerase chain reaction
(supplemental Figure 2) but do not differentiate to osteoblasts in vitro.
This is consistent with other cellular constituents of marrow niches but
not mesenchymal stem-like cells.37 Given that osteoblasts have been
shown to flatten after several days of granulocyte colony-stimulating
factor (G-CSF) exposure,34,38,39 we explored the possible role of
G-CSF on our cell population. However, flow cytometric evaluation of
a G-CSF receptor did not demonstrate expression. Finally, we
identified a CD45–F4/80lo population among the bone-lining cells in
normal C57BL/6 mice without lineage tracing, affirming the existence
of these unique cells (Figure 5F).
Discussion
Quite unexpectedly, we have unambiguously identified a novel
hematopoietic-derived cell residing at the marrow endosteal surface
that can be identified by the unique CD45–F4/80lo phenotype. The
striking correlation of our DT depletion data are consistent with
CD45–F4/80lo cells possibly being critical regulators of donor HSC
engraftment through modulation of niche osteoblast morphology.
These cells are distinct from the CD115intF4/801CD1691 macro-
phages described by Chow et al40 that have been shown to be active
in the retention of HSCs within the stem cell niche and the
mesenchymal stem cells described by Mendez-Ferrer et al.37 These
cells seem to express nestin, which is consistent with adrenergic
input affecting the regulatory functions.41
We have previously shown that marrow microenvironment remod-
eling in response to radioablation, which includes osteoblast
enlargement, osteoblast proliferation, and megakaryocyte migra-
tion, is critical for efficient HSC engraftment.12,28,31 We have
shown herein that endosteal osteoblast morphology, which could
be regulated by CD45–F4/80lo cells, is an important attribute of
postablation niche remodeling, which influences the ability of the
niche to engraft donor HSCs. Cell morphology affects membrane
biophysical properties and plays a role in adhesion of HSCs within
the marrow space.34,42 This notion is supported by studies showing
that upon adrenergic stimulation from the nervous system,
osteoblasts flatten and stiffen, thus altering their adhesiveness for
HSCs and contributing to HSC mobilization from the marrow
niche.34,42 Indeed, that cell size and shape alter adhesion properties
is a recurrent theme in developmental biology.43,44 Endosteal
osteoblast morphology may conceivably provide a marker for the
regulatory cell impacts on marrow adaptations during HCT that
foster HSC engraftment.
Given that host megakaryocytes are required for efficient HSC
engraftment12 and that hematopoietic depletion rids the marrow of
approximately 80% of megakaryocytes, why is megakaryocyte
depletion not the underlying explanation for the lack of observed
engraftment? We previously reported that complete blockade of
megakaryocyte migration with preservation of osteoblast enlargement
and proliferation leads to diminished but not abolished HSC
engraftment. The ;40% of remaining megakaryocytes that migrate
to the proliferating, flattened osteoblasts would be expected to
facilitate a low but measurable level of HSC engraftment.12 However,
we have shown in this study that donor engraftment was not detected,
and therefore, megakaryocytes, although they are necessary for
engraftment (as shown by our previous study), are not sufficient for
engraftment in the absence of the appropriate osteoblast morphologic
change. Collectively, our data suggest that although osteoblast
proliferation and megakaryocyte migration are necessary for success-
ful long-term engraftment,12,28 osteoblast thickness may be critical for
efficient HSC retention in the marrow after homing.
The finding of F4/80lo on this cell suggests that this cell derives from
the monocyte/macrophage lineage; however, monocyte lineage
depletion by DT and clodronate did not show a morphologic change
within the marrow space. Moreover, the classic markers of
monocytes and macrophages were not expressed by these cells.
Given that we attained effective but not complete depletion with
each model, this cell conceivably could be a macrophage variant
that survived depletion in both models and has lost CD45
expression during its development. Further evaluation will help
characterize this murine cell and identify potential targets for human
study because the human homolog of F4/80 is the eosinophil-
specific receptor EMR1.45
Finally, is the biology we have identified germane to patient care?
HSC ablation by TBI has been the backbone of myeloablative HCT
preparation for patients with recurrent acute leukemia as well as other
BM diseases. Multiple reports have shown superior outcomes in
event-free survival in patients with relapsed leukemia treated with TBI
compared with those treated with myeloablative chemotherapy
alone.46-49 Assessment of the BM morphology after chemotherapy
alone was evaluated, and the extent of endosteal cell expansion after
myeloablative conditioning with busulfan and cyclophosphamide was
comparable to that seen with myeloablative TBI. These findings
suggests that our current results are due to hematopoietic ablation
but not specifically TBI. Thus, we suggest that our observations are
highly relevant to clinical HCT. Moreover, the use of TBI in this study
allows for direct comparison with our previous work. Our future work
will, in part, focus on approaches to leverage this biology to hasten
the time to engraftment in the clinical setting.
Our data provide 3 key findings. First, we unambiguously identified
a novel CD45–F4/80lo cell that resides within the bone among
the endosteal osteoblasts but is derived from hematopoietic
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progenitors. Second, in situ depletion of hematopoietic cells before
conventional radioablation results in strikingly flattened endosteal
osteoblasts. And third, targeted depletion of hematopoietic cells
before radioablation generates a niche defect that abrogates donor
HSC engraftment. Our conclusions rely heavily on DT/iDTR in situ
depletion of hematopoietic cells using transgenic mice with tissue-
specific Cre expression. The primary pitfall of this strategy is lineage
infidelity of the promoter, which leads to the unintended depletion
of cells other than those targeted. To mitigate the risk of
unknowingly generating erroneous results, we used 2 different trans-
genic constructs that used 2 different hematopoietic-specific
promoters. We were able to replicate our findings with both
CD45- and Vav1-directed Cre expression, which underscores the
rigor of our conclusions.
Future investigations will be aimed at identifying a unique global
marker of our novel cell that will allow for selective depletion to
further assess its role in the hematopoietic niche, HSC engraftment,
and osteoblast morphology. With pan-CD45 depletion, we
recognize the possibility that systemic inflammation above baseline
may account for the engraftment defect; however, in our studies the
mice did not display a phenotype consistent with a lethal systemic
inflammatory reaction, and timing of death was most consistent with
aplasia. Endothelium is disrupted with TBI, and supportive stromal
elements such as mesenchymal stromal cells would not likely be
affected by DT injection. In addition, the observed flattened
osteoblast morphology cannot be readily explained by systemic
inflammation. Although the mechanistic link between depletion of
our novel cell and osteoblast morphology remains to be determined,
previous studies performed by our group12,28,31 and others32,34,42
suggest an important role for osteoblast morphology in the retention
of HSCs. Moreover, our newly identified CD45–F4/80lo cell may
prove to be an important constituent of the stem cell niche, even if it
does not regulate osteoblast morphology.
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